You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 298 No. 6, August 8, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Women's Health, Other
 •Alert me on articles by topic

Hormone Therapy and Cardiovascular Risk

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Rossouw and colleagues1 conclude that use of estrogen among women aged 50 to 59 years may not increase CHD risk, based on combined data from the CEE and CEE + MPA trials of the WHI. However, temporal trends in the use of hormone therapy may complicate the interpretation of their data.

From the early 1980s to the mid-1990s, the prevalence of hormone therapy use among postmenopausal women in the United States increased significantly to approximately 30% among women aged 60 to 74 years and 47% among women aged 50 to 59 years.2-3 In general, women receiving hormone therapy who subsequently developed breast cancer or venous thromboembolism would have been taken off this therapy permanently and would not have entered WHI, thus creating a "survivor effect" among previous hormone therapy users who did enter the trial. A hormone therapy survivor effect has been noted in previous analyses4 and is . . . [Full Text of this Article]

Lynn E. T. Shaffer, MS
shaffel@ohiohealth.com
OhioHealth Research Institute

Carl A. Krantz, MD
Riverside Methodist Hospital
Columbus, Ohio


RELATED LETTERS

Hormone Therapy and Cardiovascular Risk
Samuel Shapiro
JAMA. 2007;298(6):623.
EXTRACT | FULL TEXT  

Hormone Therapy and Cardiovascular Risk—Reply
Jacques E. Rossouw, Ross L. Prentice, Andrea Z. LaCroix, LieLing Wu, JoAnn E. Manson, David Barad, Vanessa M. Barnabei, Marcia Ko, Karen Margolis, and Marcia Stefanick
JAMA. 2007;298(6):624-625.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Jacques E. Rossouw, Ross L. Prentice, JoAnn E. Manson, LieLing Wu, David Barad, Vanessa M. Barnabei, Marcia Ko, Andrea Z. LaCroix, Karen L. Margolis, and Marcia L. Stefanick
JAMA. 2007;297(13):1465-1477.
ABSTRACT | FULL TEXT  

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee
JAMA. 2004;291(14):1701-1712.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.